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Abstract
Background: Safety data regarding exposure to artemisinin-based combination therapy in pregnancy are limited.
This prospective cohort study conducted in Zambia evaluated the safety of artemether-lumefantrine (AL) in
pregnant women with malaria.
Methods: Pregnant women attending antenatal clinics were assigned to groups based on the drug used to treat
their most recent malaria episode (AL vs. sulphadoxine-pyrimethamine, SP). Safety was assessed using standard and
pregnancy-specific parameters. Post-delivery follow-up was six weeks for mothers and 12 months for live births.
Primary outcome was perinatal mortality (stillbirth or neonatal death within seven days after birth).
Results: Data from 1,001 pregnant women (AL n = 495; SP n = 506) and 933 newborns (AL n = 466; SP n = 467)
showed: perinatal mortality (AL 4.2%; SP 5.0%), comprised of early neonatal mortality (each group 2.3%), stillbirths
(AL 1.9%; SP 2.7%); preterm deliveries (AL 14.1%; SP 17.4% of foetuses); and gestational age-adjusted low birth
weight (AL 9.0%; SP 7.7%). Infant birth defect incidence was 1.8% AL and 1.6% SP, excluding umbilical hernia.
Abortions prior to antenatal care could not be determined: abortion occurred in 4.5% of women treated with AL
during their first trimester; none were reported in the 133 women exposed to SP and/or quinine during their first
trimester. Overall development (including neurological assessment) was similar in both groups.
Conclusions: These data suggest that exposure to AL in pregnancy, including first trimester, is not associated with
particular safety risks in terms of perinatal mortality, malformations, or developmental impairment. However, more
data are required on AL use during the first trimester.
Background
More than 30 million women become pregnant each
year in malaria-endemic areas of sub-Saharan Africa [1].
Malaria during pregnancy causes adverse outcomes,
including abortion, anaemia, and low infant birth
weight, with the latter complication due to foetal growth
restriction and preterm delivery [2,3]. An important pre-
ventative strategy in highly endemic areas is intermittent
preventive treatment (IPT) with sulphadoxine-pyri-
methamine (SP) [4], and as SP becomes less effective
with increasing Plasmodium falciparum resistance [5],
effective treatment during pregnancy becomes more
important.
The World Health Organization (WHO) recommends
artemisinin-based combination therapy (ACT) as first-
line treatment of P. falciparum malaria [6]. These guide-
lines state that artemisinin derivatives should be used to
treat uncomplicated falciparum malaria in the second
and third trimesters of pregnancy [6,7], but that they
should not be used in the first trimester unless they are
the only treatment available [6,7], or if the patient’s life
is threatened, or if treatment with quinine plus clinda-
mycin has failed [6]. The guidelines take into account
the greater confidence regarding the safety of ACT
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the scarcity of data on first trimester exposure versus
the risk of embryotoxicity or death [7,12,13].
Artemether-lumefantrine (AL; Coartem®, Novartis
Pharma AG) is currently the most widely used ACT for
acute, uncomplicated P. falciparum malaria. Zambia was
one of the first countries in Africa to replace SP with
AL as first-line therapy for malaria treatment, which
occurred in 2004 [14]. Here, the results of a Zambian
multi-centre, prospective cohort study to evaluate the
safety of AL used to treat symptomatic malaria in preg-
nancy are described.
Methods
Study population
The study was carried out in Zambia at four antenatal
clinics in the districts of Choma, Ndola and Lusaka.
Data were collected between October 2004 and July
2008. Pregnant women were eligible for inclusion if they
had received AL or SP for the treatment of malaria.
Diagnosis was clinically or parasitologically confirmed.
SP was the standard anti-malarial treatment during
pregnancy and also used for IPT. Pregnant women were
assigned to exposure groups according to the treatment
received for the “index episode”, defined as the most
recently treated malaria episode prior to study entry.
Study objectives and procedures
The primary endpoint was the incidence of perinatal
mortality (stillbirth or neonatal death within 7 days of
birth). Secondary outcome measures were gestational
age at delivery and birth weight adjusted for gestational
age. In the absence of data on birth weight adjusted for
gestational age from Zambia, the Zimbabwean birth
weight data adjusted for gestational age as published by
Munjanja & Masona in 1990 [15] was used. A newborn
was considered to have low birth weight if the observed
birth weight was lower than the corresponding 5
th per-
centile of the Zimbabwean birth weight, according to
gestational age in keeping with international standards.
In addition, the following exploratory endpoints were
assessed: frequency of spontaneous abortion, preterm
delivery, neonatal mortality, maternal mortality, major
and minor birth defects, and infant development.
Women attending the antenatal clinic were enrolled if
they reported receiving treatment with either AL (20 mg
artemether and 120 mg lumefantrine) or SP (1500 mg
sulphadoxine plus 75 mg pyrimethamine) according to
label recommendations. Exposure was verified by docu-
mentation from their outpatient (clinic) files, which also
detailed diagnostic procedures performed, and dosage of
any concomitant medication given. As per government
policy, women received SP, at the same doses as
described above, during the second or third trimester as
IPT. Treatment with any drug, including anti-malarials,
prior to or after the index episode was recorded.
Women visited the antenatal clinic for assessment of
safety parameters at baseline/enrolment, four weeks
post-enrolment, four weeks pre-delivery, at delivery, and
at six weeks post-delivery. Infants were followed up at
six weeks, 14 weeks, and at 12 months after birth.
Safety assessments included monitoring and recording
all adverse events (AEs) and serious adverse events (SAEs)
up to six weeks after delivery. Pregnancy-specific assess-
ments included rates of perinatal mortality defined as still-
birth (>28 weeks gestation) and early neonatal death
(within seven days of birth), neonatal mortality (≤28 days
of birth), maternal mortality (up to six weeks post-deliv-
ery), spontaneous abortion (≤28 weeks gestation), still-
birth, preterm delivery (≤37 completed weeks), incidence
of low birth weight, gestational age at delivery (estimated
from the last menstrual period [LMP], or by a develop-
mental score [Dubowitz assessment] [16], if the LMP was
unknown), and incidence of major and minor birth
defects. Concomitant infections were recorded. Minor/
major birth malformations were documented using a
checklist. Neurodevelopmental assessment was performed
at 14 weeks and 12 months after birth. The development
of infants was assessed by the investigators either through
a general assessment (e.g. smiling, lifting head, sitting
unsupported, standing without assistance, crawling) or the
Shoklo neurodevelopment assessment [17], or both.
This study was designed, implemented, and reported
in accordance with ICH Good Clinical Practice, applic-
able local regulations, and the Declaration of Helsinki.
The study protocol was approved by the local Ethics
Review Committee of the Tropical Diseases Research
Centre, Zambia, and WHO Ethics Review Committee,
Geneva. All participants, or their parent/guardian (if the
subject was a minor), gave written or finger-marked
informed consent before study entry.
An independent Study Advisory Committee (SAC)
reviewed unblinded data for 677 women and 392 infants
on four occasions during the study and all data at the
end of the study.
Statistical analysis
Perinatal mortality was summarized by exposure (AL or
SP) for the index malaria episode, together with tradi-
tional asymptotic as well as Pearson-Clopper one-sample
two-sided 95% confidence intervals (CI). No formal test-
ing for statistical significance between the two exposure
groups was performed; instead, 95% CIs for the differ-
ence in proportions between the groups were con-
structed using traditional asymptotic methods and the
Wilson score method without continuity correction. The
odds ratio (with two-sided 95% CI) was calculated for
perinatal mortality. Women who discontinued the study
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were not taken into account in the primary analysis.
However, the robustness of the results was assessed by
supportive analyses applying multiple missing data
imputation techniques [18].
The propensity score technique assessing pre-defined
baseline factors (five pregnancy-related and 10 disease-
related factors) was used to mitigate the potential chan-
nelling effect due to non-random assignment of therapy
[19]. With the targeted sample size of 500 patients in
each group, a two-sided 95% CI for precision on
observed perinatal mortality (primary endpoint) would
vary between 3% and 7% for an assumed background
incidence of 5% in the Zambian population [20]. This
precision of estimation was deemed satisfactory for a
pilot study of this type. All data analyses were carried
out according to a pre-established analysis plan.
Results
Demographics and clinical characteristics
A total of 1,001 pregnant women were enrolled, of
whom 84.4% (845/1001) completed the study to six
weeks after delivery (Figure 1). Demographic and clinical
characteristics are shown in Table 1. Among the women
Figure 1 Participant flowchart. AL exposure group 9 pairs of twins; SP exposure group 7 pairs of twins.
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Page 3 of 12Table 1 Demographic and clinical characteristics of exposure groups at enrolment and anti-malarial treatment during
current pregnancy
Exposure groups* Total
Artemether-
lumefantrine
(N = 495)
Sulphadoxine-
pyrimethamine
(N = 506)
(N =
1001)
Age - n (%)
<20 years 79 (16.0) 81 (16.0) 160 (16.0)
20-24 years 167 (33.7) 151 (29.8) 318 (31.8)
25-29 years 144 (29.1) 148 (29.2) 292 (29.2)
30-39 years 101 (20.4) 119 (23.5) 220 (22.0)
≥ 40 years 4 (0.8) 7 (1.4) 11 (1.1)
Time of index malaria episode relative to LMP - n (%)
Before LMP 0 (0) 2 (0.4) 2 (0.2)
Date of LMP to 12 weeks 145 (29.3) 115 (22.7) 260 (26.0)
>12 to 24 weeks 169 (34.1) 205 (40.5) 374 (37.4)
>24 weeks 162 (32.7) 161 (31.8) 323 (32.3)
LMP incomplete/unknown 19 (3.8) 23 (4.5) 42 (4.2)
Treatment courses during first trimester including IPT with SP - n
(%)
Only AL 142 (28.7) 5 (1.0) 147 (14.7)
Only SP 7 (1.4) 120 (23.7) 127 (12.7)
AL and SP 8 (1.6) 1 (0.2) 9 (0.9)
SP plus quinine 0 (0) 2 (0.4) 2 (0.2)
Only quinine 2 (0.4) 2 (0.4) 4 (0.4)
None (including unknown LMP date) 336 (67.9) 376 (74.3) 712 (71.1)
Treatment received during current pregnancy **- n (%) (N = 473) (N = 478) (N = 951)
Only AL or SP 51 (10.8) 449 (93.9) 500 (52.6)
Both AL and SP 412 (87.1) 13 (2.7) 425 (44.7)
AL or SP plus quinine 1 (0.2) 13 (2.7) 14 (1.5)
Both AL and SP plus quinine 9 (1.9) 3 (0.6) 12 (1.3)
Alcohol status (current) (N = 495) (N = 506) (N =
1001)
Non-drinker 441 (89.1) 437 (86.4) 878 (87.7)
Drinker 14 (2.8) 17 (3.4) 31 (3.1)
Unknown 40 (8.1) 52 (10.3) 92 (9.2)
Alcohol intake frequency
Low 11 (2.2) 11 (2.2) 22 (2.2)
Medium 3 (0.6) 5 (1.0) 8 (0.8)
High 0 1 (0.2) 1 (0.1)
Tobacco smoking history (current)
Non-smoker 455 (91.9) 454 (89.7) 909 (90.8)
Smoker 0 0 0
Unknown 40 (8.1) 52 (10.3) 92 (9.2)
Enrolled population: pregnant women who gave informed consent.
*Exposure groups represent the treatment given to the pregnant woman for the falciparum malaria episode that had occurred most recently prior to enrolment
(index episode).
** Data from women with known delivery status.
AL = artemether-lumefantrine
IPT = intermittent preventive treatment (with SP)
LMP = last menstrual period
SP = sulphadoxine-pyrimethamine
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schooling at the primary level and 52.2% had received
some degree of secondary education.
The index episode was predominantly diagnosed based
on symptoms: malaria was unconfirmed in 82.0% of the
AL and 87.2% of the SP exposure groups. Details of
anti-malarial treatment received during the current
pregnancy are shown in Table 1. The majority of
women with known delivery status in the AL group
(412/473; 87.1%) had received both AL and SP (as IPT)
during the current pregnancy. Conversely, most women
in the SP group had received only SP for treatment
(449/478; 93.9%) and IPT prophylaxis in the 2
nd and 3
rd
trimesters, in accordance with National Health policy in
Zambia; a single dose of 1500 mg of sulphadoxine plus
75 mg pyrimethamine was used for treatment or pro-
phylaxis. In total, 2.7% (13/478) of women in the SP
group were exposed to both AL and SP. Most women
received two to four courses of anti-malarial treatment
during the pregnancy, including IPT. A small proportion
of women in each group (AL 2.1%; SP 3.3%) were also
exposed to quinine. Approximately 70% of enrolled
women had taken their first anti-malarial treatment 12
weeks after their LMP. In total, 156 women (150/495
[30.3%] from the AL group, plus 6 from the SP group)
received AL treatment during the first trimester, while
138 women (123/506 [24.3%] from the SP group, plus
15 from the AL group) received SP treatment during
the first trimester.
All patients reported taking the full prescribed
course of anti-malarial treatment, and very few (<0.4%)
reported vomiting the medication. More than 95% of
all enrolled women received at least one concomitant
medication (other than anti-malarial therapy), most
commonly folic acid and oral iron preparations. All
women were counselled for HIV testing. Approxi-
mately 30% of women in the AL group and 38% in the
SP exposure group were tested for HIV: overall, 22%
of women with a test result were reported as HIV-
positive.
Pregnancy outcomes
A summary of pregnancy outcomes is shown in Table 2.
Overall perinatal mortality was similar for both exposure
groups (Table 3) (AL 4.2% [asymptotic 95% CI 2.4 -
6.0]; SP 5.0% [asymptotic 95% CI 3.1 - 6.9]; odds ratio
[AL versus SP] 0.84 [asymptotic 95% CI 0.45 - 1.53]).
First trimester perinatal mortality is reported in detail
below. Subgroup analyses on perinatal mortality did not
show any significant between-group differences.
Perinatal mortality status was missing for 6.2% of
women due to abortion (1.2%) or withdrawal prior to
delivery (5.0%). However, multiple imputation analyses
demonstrated that the results were robust with respect
to missing data.
Women treated with AL for the index episode had a
higher frequency of confirmed malaria in comparison
with women treated with SP. An analysis to correct for
any possible channelling bias showed no effect on peri-
natal mortality due to more AL patients having con-
firmed malaria (adjusted odds ratio of 0.79 [95% Wald
CI 0.43 - 1.46] versus the observed unadjusted odds
ratio of 0.84 [asymptotic 95% CI 0.45 - 1.53]).
Stillbirths occurred in 1.9% of the AL group and in
2.7% of the SP group. Of the nine mothers who had
stillbirths in the AL group, AL was the last exposure in
three cases; eight women had been exposed to SP for
IPT, six were exposed after the AL-treated index epi-
sode, and two before it. Thirteen women in the SP
group had stillbirths: in five cases, SP was the last expo-
sure (as treatment for the index episode); six of the thir-
teen women had IPT; and two women were treated with
quinine for additional episodes of malaria.
Early neonatal death was similar for each exposure
group (2.3% for each group). In the AL group, four of
the 11 neonatal deaths occurred after delivery at home.
All 11 neonatal deaths in the SP group occurred after
delivery at a hospital or health centre.
There were seven cases of abortion in the AL group,
all occurring in women who were exposed to AL during
their first trimester (further details below); the last anti-
Table 2 Pregnancy outcome by exposure group
Pregnancy outcome - n (%) Artemether-lumefantrine
(N = 504)
Sulphadoxine-pyrimethamine
(N = 516)
Abortion (≤28 weeks of gestation) 7* (1.4) 8** (1.6)
Stillbirth (>28 weeks of gestation) 9 (1.8) 13 (2.5)
Preterm delivery (<37 completed weeks of gestation) 71 (14.1) 90 (17.4)
Full term delivery (≥37 completed weeks of gestation) 395 (78.4) 377 (73.1)
Unknown (mother withdrawn prior to delivery) 22 (4.4) 28 (5.4)
Enrolled population: newborns, stillbirths, and aborted foetuses or pregnant women who were withdrawn prior to delivery.
* All first trimester exposures.
**5 abortions: one woman with triplets, one with twins - none had first trimester exposure.
One patient from the AL group had an ectopic pregnancy with laparotomy performed to remove the foetus. This patient has pregnancy outcome “unknown” as
she was withdrawn due to an adverse event (ectopic pregnancy) prior to “delivery”.
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and in the remaining case SP was given for treatment of
a malaria episode occurring after the index episode.
Eight abortions occurred in five women in the SP group,
all second or third trimester exposures (one was carry-
ing triplets, another was carrying twins): the last anti-
malarial exposure was SP (index episode) in one case,
SP (IPT) in three cases, and quinine (additional malaria
episode) in the remaining case.
Infant outcomes at birth
Infant outcomes are summarized in Table 4. Low birth
weight according to gestational age occurred in 9.0% of
the AL and 7.7% of the SP group. Mean and median
birth weights, head circumference, body length, and sex
distribution were similar in both exposure groups. Mean
and median gestational ages determined using LMP
were comparable for the two groups (39.0 weeks each),
as were the values calculated from the Dubowitz test
(mean/median: AL group 37.6/37.7 weeks; SP group
38.2/38.1 weeks).
Birth defects in infants were detected by midwives in
6.5% of the AL group and 4.1% of the SP group (Table
5). The between-group difference was largely due to a
higher rate of umbilical hernia in the AL group (AL
4.7%; SP 2.7%). The majority of these had resolved by
the 12 month evaluation (Table 6). Excluding umbilical
hernia, which is a common reversible defect in African
children [21,22], the infant birth defect frequency was
1.8% for AL and 1.6% for SP. There was no pattern of
distribution of any birth defect in either exposure group.
In the AL group, multiple birth defects were reported in
two infants: one had trisomy 21, the other had trisomy
18. Polydactyly was reported in seven infants and
occurred in a similar proportion in each group (AL
0.7%; SP 0.9%).
Infant outcomes and developmental assessments from
birth to 12 months
Mean and median height and weight were very similar
in both groups at birth, 14 weeks, and at 12 months
after delivery (data not shown). The general develop-
mental assessment in 833 infants (427 AL; 406 SP) at 14
Table 3 Perinatal mortality (stillbirths plus neonatal deaths) by exposure group
Artemether-lumefantrine
(N = 475)
Sulphadoxine-pyrimethamine
(N = 480)
Perinatal mortality (primary outcome) - n
(%)
20 (4.2) 24 (5.0)
Asymptotic 95% CI 2.4 - 6.0 3.1 - 6.9
Pearson-Clopper 95% CI 2.6 - 6.4 3.2 - 7.3
Stillbirth - n (%) 9 (1.9) 13 (2.7)
Neonatal death ≤7 days after birth - n
(%)
11 (2.3) 11 (2.3)
Exposure to anti-malarial agent(s) during first trimester*
AL only (N =
135)
AL + SP (N =
7)
SP or/and quinine (N =
129)
None (N =
644)
Unknown (N =
40)
Perinatal mortality - n (%) 6 (4.4) 1 (14.3) 5 (3.9) 31 (4.8) 1 (2.5)
Stillbirth (>28 weeks gestation) 2 (1.5) 0 (0) 3 (2.3) 17 (2.6) 0 (0)
Death ≤7 days after birth 4 (3.0) 1 (14.3) 2 (1.6) 14 (2.2) 1 (2.5)
Enrolled population: newborns and stillbirths.
Perinatal mortality: stillbirth or early neonatal death within 7 days after birth.
AL = artemether-lumefantrine; CI = confidence interval; SP = sulphadoxine-pyrimethamine.
* Data from newborns and stillbirths with known delivery status.
Table 4 Gestational age and weight of infants at birth by
exposure group
Artemether-
lumefantrine
(N = 466)
Sulphadoxine-
pyrimethamine
(N = 467)
Gestational age at delivery, determined by LMP
Number of
observations
448 445
Mean/Median weeks 39.0/39.0 38.9/39.0
Distribution - n (%)
≤28 weeks 5 (1.1) 2 (0.4)
>28 to <37
weeks
58 (12.4) 85 (18.2)
≥37 weeks 385 (82.6) 358 (76.7)
Missing 18 (3.9) 22 (4.7)
Birth weight - g
Number of
observations
448 444
Mean (SD) 3058.3 (515.96) 3039.2 (495.26)
Median (Range) 3000 (900 - 4700) 3000 (1300 - 4500)
Enrolled population: newborn infants.
LMP = last menstrual period
Patients with a missing birth weight or a missing gestational age were not
taken into account in this Table.
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Page 6 of 12weeks (smiling, lifting head) and at 12 months (sitting
unsupported, standing without assistance, crawling) was
also similar for each group, and virtually all infants met
their expected developmental milestones. In addition,
infants of mothers only exposed to AL or SP compared
well with the overall group.
Data from the Shoklo neurodevelopmental evaluation,
performed in 530 infants (298 AL; 232 SP), revealed very
similar mean and median values for each exposure group.
Tone and behaviour scores were similar at 14 weeks and
12 months, but motor milestone and coordination scores
increased considerably over the study period. No differ-
ences in Shoklo neurodevelopment scores were observed
in infants of mothers who had been exposed only to AL or
to SP: more than 98% of infants assessed achieved a score
of “good” or “excellent” at 14 weeks and at 12 months.
Neonatal mortality rate (death within 28 days of birth)
was 3.0% in each group. In many cases the cause of
death was unknown and the most common reported
causes were prematurity and asphyxia.
Exposure to anti-malarials in the first trimester
(exploratory analyses)
A total of 156 women (150/495 [30.3%] from the AL
plus 6 from the SP group) received AL treatment during
the first trimester, primarily for treatment of the index
episode (Table 1). Foetuses of women exposed to AL
only during the first trimester had a similar rate of full-
term delivery to those who had no first trimester anti-
malarial exposure (AL alone: 75.3% [113/150]; none:
76.5% [523/684]). The rate of preterm delivery was high-
est in foetuses of women exposed to SP and/or quinine
during the first trimester (SP and/or quinine: 20.7% [28/
135]; AL alone 13.3% [20/150]; none 15.2% [104/684])
(Table 7).
A total of 159 foetuses were exposed to AL during the
first trimester, either AL only (n = 150) or AL plus SP
(n = 9) (Table 7). Six abortions occurred in this popula-
tion (AL alone: 4 cases; AL plus SP: 2 cases) giving a
rate of 3.8% (Table 8). One further abortion occurred in
a woman who was likely to have taken AL during the
first trimester (incomplete LMP date). Confounding fac-
tors were present in four cases; one had syphilis, two
had multiple malarial episodes, and one received conco-
mitant treatment with salbutamol and AL for a threa-
tened abortion. In 135 foetuses exposed to SP and/or
quinine during the first trimester, no abortions were
reported.
Perinatal mortality was very similar whether first tri-
mester exposure was to AL alone, or to SP and/or qui-
nine, or if no anti-malarial therapy had been received
(Table 3). Among women who received AL during the
first trimester, 4.3% (6/140) newborns died within 28
days after birth compared with 3.0% (19/627) among
women who received no anti-malarials and 1.6% (2/126)
among women who only received SP and/or quinine
during the first trimester.
Birth weight (adjusted for gestational age or not)
showed no notable differences between the groups.
The incidence of malformations in babies born to
mothers who received AL only in the first trimester was
6.9% (9/130); eight of these nine cases were umbilical
hernias, and the remaining baby was reported as having
small genital labia, lanugo, and a small nose (Table 6).
The malformation rate in infants from women exposed
to other anti-malarial agents was 6.6% (8/121), and 4.5%
(27/596) in those with no anti-malarial exposure in the
first trimester.
The Shoklo neurodevelopmental assessment of infants
born to women exposed to AL in the first trimester
were very similar to results for SP: 98.8% (83/84) of
infants from the AL group achieved a score of “good” or
Table 5 Birth defects reported from the time of delivery
to 14 weeks by exposure group
Artemether-
lumefantrine
(N = 466)
Sulphadoxine-
pyrimethamine
(N = 467)
Total number infants with
malformations
a - n (%)
29/449
b (6.5) 18/444
b (4.1)
Diagnosis of congenital
anomaly/birth defect
Umbilical hernia 21 (4.7) 12 (2.7)
Polydactyly 3 (0.7) 4 (0.9)
Dermal cyst 0 (-) 1 (0.2)
Ear malformation 0 (-) 1 (0.2)
Genitourinary system: small
labia
c
1 (0.2) 0 (-)
Hair: lanugo
c 1 (0.2) 0 (-)
Inguinal hernia 0 (-) 1 (0.2)
Limbs: hyperextensibility of
joint
1 (0.2) 0 (-)
Nose: small
c 1 (0.2) 0 (-)
Skin hyperpigmentation 1 (0.2) 0 (-)
Trisomy 18
d 1 (0.2) 0 (-)
Trisomy 21
e 1 (0.2) 0 (-)
Enrolled population: newborn infants.
No distinction was made between major and minor birth defects on the case
report form.
aAny malformation = any finding other than normal or any diagnosis of
congenital anomaly/birth defect reported.
bNumber of newborn infants with assessment performed at least once at
delivery, 6 weeks, or 14 weeks post-delivery. No assessments were available
for 17 infants in the AL group and 23 in the SP group.
cReported in the same patient.
dReported malformations: Ears - low set; Mouth - high arched palate; Cranium
- microencephaly/anencephaly; Limbs - clenched with overlapping fingers.
eReported malformations: Ears - low set; Mouth - high arched palate; CVS
murmur; Chest - short sternum; Cranium - low occiput; Eyes - upward slanting;
Mouth - protruding tongue; Neck - short; Nose - low nasal bridge.
In the SP group, one child was reported to have had umbilical hernia and
polydactyly.
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same scores at 12 months.
General safety outcomes
A summary of common AEs is presented in Table 9.
The two groups were generally similar in their observed
AE profiles, the most notable differences being the rates
of premature delivery and of malaria as an AE, both of
which were higher in the SP group. SAEs, most com-
monly complications of pregnancy and infections,
occurred in 6.5% of women in the AL group and in
7.3% of those exposed to SP.
There were six maternal deaths during the study; one
death (0.2%) in the AL group (anaemia secondary to sponta-
neous abortion), and five deaths (1.0%) in the SP group (one
from Kaposi’s sarcoma, three from infections [pneumonia,
sepsis, and viral encephalitis], and one from “undiagnosed
illness”). Mean haemoglobin levels 4 weeks after enrolment
and at delivery were 12.0 and 11.6 g/dL in the AL group,
and 11.9 and 11.7 g/dL in the SP group, respectively.
Table 6 Birth defects reported from time of delivery until 14 weeks after birth, according to anti-malarial drug
exposure during the first trimester
Exposure to anti-malarial(s) during first trimester
AL only
(N = 133)
AL plus SP
(N = 7)
SP or/and quinine
(N = 126)
None
(N = 627)
Unknown
(N = 40)
Total number of infants with malformations (%) 9/130 (6.9) 0/7 (-) 8/121 (6.6) 27/596 (4.5) 3/39 (7.7)
Umbilical hernia
4 8 (6.2) 0 (-) 5 (4.1) 20 (3.4) 0 (-)
Polydactyly 0 (-) 0 (-) 1 (0.8) 4 (0.7) 2 (5.1)
Dermal cyst 0(-) 0 (-) 1 (0.8) 0 (-) 0 (-)
Ear malformation 0 (-) 0 (-) 1 (0.8) 0 (-) 0 (-)
Genitourinary system: small labia
1 1 (0.8) 0 (-) 0 (-) 0 (-) 0 (-)
Hair: lanugo
1 1 (0.8) 0 (-) 0 (-) 0 (-) 0 (-)
Inguinal hernia 0 (-) 0 (-) 0 (-) 1 (0.2) 0 (-)
Limbs: hyperextensibility of joint 0 (-) 0 (-) 0 (-) 0 (-) 1 (2.6)
Nose: small
1 1 (0.8) 0 (-) 0 (-) 0 (-) 0 (-)
Skin hyperpigmentation 0 (-) 0 (-) 0 (-) 1 (0.2) 0 (-)
Trisomy 18
2 0 (-) 0 (-) 0 (-) 1 (0.2) 0 (-)
Trisomy 21
3 0 (-) 0 (-) 0 (-) 1 (0.2) 0 (-)
Enrolled population: newborns.
1 All of these malformations were reported in the same patient.
2 Reported malformations in this patient: Ears - low set; Mouth - high arched palate; Cranium microencephaly/anencephaly; Limbs - clenched with overlapping
fingers.
3 Reported malformations in this patient: Ears - low set; Mouth - high arched palate; CVS murmur; Chest - short sternum; Cranium: flat occiput; Eyes - upward
slanting; Mouth: protruding tongue; Neck - short; Nose - low nasal bridge.
4 No umbilical hernia was detected at birth. Of 21 cases reported in the AL exposure group, 12 detected at week 6 were resolved by week 14. All remaining
umbilical hernias had resolved by 12 months except for one infant who died prior to 12 months from a febrile illness. The mother of one infant with an
umbilical hernia had received quinine during the first trimester of pregnancy, before AL treatment of the index episode (not in the first trimester) and another
had received SP during the first trimester. In eight additional cases, the mother had received AL treatment in the first trimester, in each case to treat the index
episode of malaria. In the SP group, among 12 infants with umbilical hernias, 7 had resolved by week 14, the remainder by month 12, with the exception of 1
case lost to follow-up, and one infant who died from pneumonia.
Table 7 Pregnancy outcome by exposure group, according to anti-malarial drug exposure during the first trimester
Exposure to anti-malarial(s) during first trimester
AL only
(N = 150)
AL plus SP
(N = 9)
SP or/and quinine
(N = 135)
None
(N = 684)
Unknown
(N = 42)
Pregnancy outcome - n (%)
Abortion (≤28 weeks) 4 (2.7) 2 (22.2) 0 (-) 8* (1.2) 1** (2.4)
Stillbirth (>28 weeks) 2 (1.3) 0 (-) 3 (2.2) 17 (2.5) 0 (-)
Preterm delivery (<37 weeks) 20 (13.3) 1 (11.1) 28 (20.7) 104 (15.2) 8 (19.0)
Full term delivery (≥37 weeks) 113 (75.3) 6 (66.7) 98 (72.6) 523 (76.5) 32 (76.2)
Unknown (mother withdrawn prior to delivery) 11 (7.3) 0 (-) 6 (4.4) 32 (4.7) 1 (2.4)
Enrolled population: newborns, stillbirths and aborted foetuses
AL = artemether-lumefantrine; SP = sulphadoxine-pyrimethamine
*5 abortions: one woman with triplets, one with twins
** Incomplete date of last menstrual period, therefore, counted as unknown first trimester exposure (a woman who was likely to have taken AL during the first
trimester)
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Page 8 of 12The incidence of non-fatal SAEs was similar (AL 21.8%
[108/495] vs. SP 23.3% [118/506]). The most frequent
non-fatal SAEs were related to pregnancy and birth, spe-
cifically premature delivery (AL 13.7%; SP 17.2%), still-
birth, cephalo-pelvic disproportion, and abortion. Other
SAEs included infections (AL 0.6%; SP 0.8%), of which
there were three cases of severe malaria in the SP group.
Discussion
WHO treatment guidelines exclude artemisinin com-
pounds for use in the first trimester of pregnancy unless
there is no alternative, or the mother’sl i f ei sa ts t a k e
[6,7]. Preclinical data have raised concerns for ACT
exposure in early pregnancy [7,12,13], and yet, despite
an unprecedented roll out of ACT, there are only 125
reported cases of human first trimester exposure to arte-
misinins, albeit with no adverse outcomes [7], a number
insufficient to be reassuring regarding safety [7,23,24].
This report is based on maternal and birth outcomes in
the largest series of prospectively followed ACT-exposed
pregnancies, in which there were 495 women in the AL
exposure group, and 156 were exposed during the first
Table 8 Abortion occurring in women treated with artemether-lumefantrine
Case Time of abortion
(gestation week)
Time of AL
treatment (gestation
week)
Reason for
AL treatment
Comments
A 13 9 Index episode Syphilis at Week 10
B 10 6 Index episode -
C 18 6 Index episode -
D 15 7 Index episode Viable embryo at Week 11 on ultrasound
E2 7
a 6 and 16 Index episode 3 malaria episodes at Weeks 6, 11 (received SP), and 16
F 22 10 Non-index
episode
2 previous spontaneous abortions; 3 malaria episodes at Weeks 7 (received SP),
10, and 22 (received SP); at Week 20 severe respiratory tract infection, anaemia,
oral candidiasis, and immunosuppression (suspected HIV positive): spontaneous
abortion at Week 22, followed by maternal death 24 hours later
G
b 6 days after AL
treatment
Between Weeks 6 and
9
Index episode Treatment with salbutamol for threatened abortion during AL treatment
All cases of abortion occurred in women who received AL during the first trimester; cases A-D, and G received AL only during the pregnancy.
Index episode: falciparum malaria episode that had occurred most recently prior to study enrolment.
AL = artemether-lumefantrine; SP = sulphadoxine-pyrimethamine
a Therapeutic abortion following intrauterine death.
b Incomplete LMP date, therefore, counted as unknown first trimester exposure.
Table 9 Common* adverse events by exposure group
MedDRA Primary System Organ Class: MedDRA Preferred Term Artemether-lumefantrine
N = 495
n (%)
Sulphadoxine-pyrimethamine
N = 506
n (%)
Total number of patients with any adverse events 171 (34.5) 186 (36.8)
Blood and lymphatic system disorders: 7 (1.4) 16 (3.4)
Anaemia 7 (1.4) 15 (3.2)
Infections and infestations: 61 (12.3) 66 (13.0)
Malaria 17 (3.4) 34 (6.7)
Syphilis 24 (4.8) 20 (4.0)
Respiratory tract infection 9 (1.8) 5 (1.0)
Urinary tract infection 5 (1.0) 5 (1.0)
Nervous system disorders: 1 (0.2) 8 (1.6)
Headache 1 (0.2) 6 (1.2)
Pregnancy, puerperium, and perinatal conditions: 108 (21.8) 120 (23.7)
Premature baby 69 (13.9) 87 (17.2)
Stillbirth 9 (1.8) 13 (2.6)
Cephalo-pelvic disproportion 11 (2.2) 6 (1.2)
Abortion spontaneous 6 (1.2) 5 (1.0)
Enrolled population: pregnant women who gave informed consent.
MedDRA = medical dictionary for regulatory activities
A pregnant woman with multiple occurrences of an adverse event is counted only once in the corresponding adverse event category.
*Preferred terms occurring in at least 1% of women in either exposure group are presented along with the corresponding primary system organ class.
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Page 9 of 12trimester. Outcomes were compared against SP, the
most widely used anti-malarial agent administered dur-
ing pregnancy. Furthermore, a prolonged follow up of
infants permitted a thorough investigation of their
development following anti-malarial exposure in utero.
The observed rate of perinatal mortality was 4.2% in
the AL group and 5.0% in the SP group, which is com-
parable with other data from malaria endemic areas
[25-27]. There were no differences between groups with
regard to neonatal mortality, maternal mortality, rates of
stillbirth, low birth weight, and infant neurological
development. Preterm delivery using reported LMP
dates (which are notoriously unreliable) was slightly
more common in the SP group (17.4%; AL group
14.1%), but the majority of infants had birth weights
consistent with full-term delivery. Anti-malarial treat-
ment was reportedly well-tolerated. Overall, 22% of 326
women with a reported test result (i.e. approximately 7%
of the women in each exposure group) had an HIV-
positive test. The overall profiles for AEs and SAEs were
unremarkable: besides pregnancy complications, most of
the commonly reported AEs and SAEs were due to
infections, which were also responsible for the majority
of maternal deaths.
Women with first trimester AL exposures did not
have a greater perinatal mortality rate compared with
SP exposure. Infant neurodevelopmental assessments
were also similar, irrespective of drug exposure in first
trimester. However, there were seven abortions in 159
foetuses exposed to AL in their first trimester, and no
abortions in 135 foetuses exposed to SP and/or quinine
in their first trimester. In four AL-exposed abortions,
the women had risk factors for abortion: two women
had three malaria episodes within the first trimester,
one woman had syphilis diagnosed 1 week post-AL
exposure, and one woman was given salbutamol for
threatened abortion concomitantly with AL therapy for
malaria. Furthermore, there was no clear relationship
between the time at which AL exposure occurred and
the occurrence of abortion; except in one case, the
abortion occurred long after anti-malarial drug inges-
tion. Women were mainly enrolled after their first tri-
mester and, therefore, this study could not determine
the potential number of abortions that occurred during
the first trimester. This may explain the lower abortion
rate observed, compared with the 12-16% spontaneous
abortion rate documented [28,29]. It is difficult to draw
any definite conclusions from the data, but further
monitoring of first trimester exposures to AL is
warranted.
The frequency of birth defects was low and the SAC
did not consider that any reported defects (excluding
the cases of trisomy) could be described as major. The
most frequent finding was umbilical hernia (AL 4.7%;
SP 2.7%) and all cases had resolved within 12 months.
Umbilical hernia has been reported in rats exposed to
artemisinins during gestation [30,31]. It is commonly
observed in African infants (17%-23%) [21,22], is not
generally considered as a “malformation” and the fre-
quency reported here was less than previously documen-
ted [21,22]. Polydactyly, another reported malformation,
is also commonly found in African infants [32,33].
Although reasons for the low incidence of major malfor-
mations in this study remain unclear, it is unlikely that
major malformations (as described by van Regemorter,
[34]) would have been missed. Cardiac defects were not
detected as cardiac auscultation and/or echocardiograms
were not routinely performed, and autopsies were not
carried out on deceased infants.
W i t hn e wd a t ao nm o r et h a n3 0 0w o m e ne x p o s e dt o
AL (referring to index episodes) during the second and
third trimester, this study substantially adds to data on
the safety of artemisinins in the later stages of preg-
nancy in African women [35,36], confirming previous
findings that AL exposure during this period is well tol-
erated and has no adverse outcomes for the mother or
her exposed foetus.
The study had both strengths and limitations. Firstly,
it was undertaken in the context of care provided at
antenatal clinics in Zambia, and represents the demo-
graphic, infectious disease, and drug exposure profile of
pregnant women coming for routine care. The acquisi-
tion of drug safety data in pregnancy via clinical trials is
associated with various difficulties, risks and costs [37].
Regulatory authorities now recommend observational
prospective designs for detecting drug exposure risks or
generating margins of reassurance regarding lack of
drug exposure risk during pregnancy [38,39]. This study
followed these recommendations. The majority of
women (>87% AL group) had received IPT with SP
prior to enrolment or thereafter (only 51 women were
exposed to AL alone), thereby protecting the women
from malaria, but also confounding the evaluation of AL
exposure. The index episode was unconfirmed by micro-
scopy or rapid diagnostic test in most (85%) partici-
pants, which is normal clinical practice at the level of
health centres in Zambia where the study was carried
o u t ,a n di ti sl i k e l yt h a ts o m eo ft h ew o m e ne x p o s e dt o
AL and SP may have had other febrile illnesses. This
does not change the validity of the information col-
lected, but prevents an analysis of whether the presence
of malaria parasites (to which the artemisinins preferen-
tially bind) changed any risk.
Gestational age was assessed by midwives either via
LMP (the primary method indicated in the protocol) or
through use of the Dubowitz test. The Dubowitz test
has been shown to be a reliable method for assessment
of gestational age in African neonates [40]. However,
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Page 10 of 12although all of the investigators received the same type
and frequency of training from the same trainers to
allow uniform standardized assessments, these results
need to be interpreted with some caution as the neona-
tal assessments were conducted over a long duration of
time at multiple sites.
A low incidence of major birth defects could either
reflect a lower risk or weaknesses in identifying these
risks [41]. On balance, however, as both groups were
prospectively monitored without knowing the outcome,
the safety data obtained reflect the unbiased outcomes
of pregnancies exposed to multiple infections and multi-
ple drugs, including anti-malarials, rather than the con-
sequences of a single well-defined treatment for a single
infectious episode.
Conclusions
With increasing resistance to SP, establishing the margin
of safety of ACT in pregnancy is critical. Results from
this cohort study confirm that exposure to AL during
later pregnancy is not associated with increased safety
risks in terms of perinatal mortality, malformations, or
infant neurodevelopment, but they also suggest that
more safety data are required on first trimester exposure
to AL and consequently for ACT in general.
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